230 related articles for article (PubMed ID: 35511432)
21. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
22. Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.
Duan J; Lv G; Zhu N; Chen X; Shao Y; Liu Y; Zhao W; Shi Y
Thorac Cancer; 2022 Apr; 13(7):947-955. PubMed ID: 35150094
[TBL] [Abstract][Full Text] [Related]
23.
Zhang N; Shen J; Gou L; Cao M; Ding W; Luo P; Zhang J
Bioengineered; 2022 May; 13(5):11577-11592. PubMed ID: 35531878
[TBL] [Abstract][Full Text] [Related]
24. Prognosis of Tumor Microenvironment in Luminal B-Type Breast Cancer.
Lv J; Ren J; Zheng J; Zhang F; Han M
Dis Markers; 2022; 2022():5621441. PubMed ID: 35242245
[TBL] [Abstract][Full Text] [Related]
25. m
Chong W; Shang L; Liu J; Fang Z; Du F; Wu H; Liu Y; Wang Z; Chen Y; Jia S; Chen L; Li L; Chen H
Theranostics; 2021; 11(5):2201-2217. PubMed ID: 33500720
[TBL] [Abstract][Full Text] [Related]
26. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in Gastric Cancer.
Xiang R; Ge Y; Song W; Ren J; Kong C; Fu T
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680930
[TBL] [Abstract][Full Text] [Related]
27. Identification of Necroptosis-related Subtypes and Characterization of Tumor Microenvironment Infiltration in Non-small Cell Lung Cancer.
Deng Y; Lin Y; Zhou B; Jing Q; Zhang W
Curr Cancer Drug Targets; 2023 Jun; ():. PubMed ID: 37469156
[TBL] [Abstract][Full Text] [Related]
28. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
29. RNA modification writer expression profiles predict clinical outcomes and guide neoadjuvant immunotherapy in non-small cell lung cancer.
Zhou B; Bie F; Zang R; Zhang M; Song P; Liu L; Peng Y; Bai G; Zhao J; Gao S
EBioMedicine; 2022 Oct; 84():104268. PubMed ID: 36116215
[TBL] [Abstract][Full Text] [Related]
30. Identification of m
Du F; Li H; Li Y; Liu Y; Li X; Dang N; Chu Q; Yan J; Fang Z; Wu H; Zhang Z; Zhu X; Li X
Front Cell Dev Biol; 2021; 9():761134. PubMed ID: 34993195
[TBL] [Abstract][Full Text] [Related]
31. Autophagy-related gene expression classification defines three molecular subtypes with distinct clinical and microenvironment cell infiltration characteristics in colon cancer.
Zhu S; Wu Q; Zhang B; Wei H; Li B; Shi W; Fang M; Zhu S; Wang L; Lang Zhou Y; Dong Y
Int Immunopharmacol; 2020 Oct; 87():106757. PubMed ID: 32769067
[TBL] [Abstract][Full Text] [Related]
32. Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC.
Tian Y; Zhai X; Yan W; Zhu H; Yu J
Cancer Med; 2021 Jan; 10(1):3-14. PubMed ID: 33230935
[TBL] [Abstract][Full Text] [Related]
33. KEAP1 and TP53 Frame Genomic, Evolutionary, and Immunologic Subtypes of Lung Adenocarcinoma With Different Sensitivity to Immunotherapy.
Scalera S; Mazzotta M; Corleone G; Sperati F; Terrenato I; Krasniqi E; Pizzuti L; Barba M; Vici P; Gallo E; Buglioni S; Visca P; Pescarmona E; Marinelli D; De Nicola F; Ciuffreda L; Goeman F; Fanciulli M; Giusti R; Vecchione A; De Maria R; Cappuzzo F; Marchetti P; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2021 Dec; 16(12):2065-2077. PubMed ID: 34450259
[TBL] [Abstract][Full Text] [Related]
34. PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
Wang H; Shan Q; Guo J; Han X; Zhao C; Li H; Wang Z
Lung Cancer; 2021 Jan; 151():76-83. PubMed ID: 33246647
[TBL] [Abstract][Full Text] [Related]
35. Immune microenvironment infiltration landscape and immune-related subtypes in prostate cancer.
Wu W; Wang X; Le W; Lu C; Li H; Zhu Y; Chen X; An W; Xu C; Wu Q; Wang L
Front Immunol; 2022; 13():1001297. PubMed ID: 36700224
[TBL] [Abstract][Full Text] [Related]
36. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
37. KAT2B is an immune infiltration-associated biomarker predicting prognosis and response to immunotherapy in non-small cell lung cancer.
Zhou X; Wang N; Zhang Y; Yu H; Wu Q
Invest New Drugs; 2022 Feb; 40(1):43-57. PubMed ID: 34499335
[TBL] [Abstract][Full Text] [Related]
38. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer.
Best SA; Gubser PM; Sethumadhavan S; Kersbergen A; Negrón Abril YL; Goldford J; Sellers K; Abeysekera W; Garnham AL; McDonald JA; Weeden CE; Anderson D; Pirman D; Roddy TP; Creek DJ; Kallies A; Kingsbury G; Sutherland KD
Cell Metab; 2022 Jun; 34(6):874-887.e6. PubMed ID: 35504291
[TBL] [Abstract][Full Text] [Related]
39. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
Marinelli D; Mazzotta M; Scalera S; Terrenato I; Sperati F; D'Ambrosio L; Pallocca M; Corleone G; Krasniqi E; Pizzuti L; Barba M; Carpano S; Vici P; Filetti M; Giusti R; Vecchione A; Occhipinti M; Gelibter A; Botticelli A; De Nicola F; Ciuffreda L; Goeman F; Gallo E; Visca P; Pescarmona E; Fanciulli M; De Maria R; Marchetti P; Ciliberto G; Maugeri-Saccà M
Ann Oncol; 2020 Dec; 31(12):1746-1754. PubMed ID: 32866624
[TBL] [Abstract][Full Text] [Related]
40. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
